Advertisement
Advertisement
U.S. Markets open in 7 hrs 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kala Pharmaceuticals, Inc. (KALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.2452+0.0059 (+2.47%)
At close: 04:00PM EDT
0.2500 +0.00 (+1.96%)
After hours: 06:30PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

    ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded fireside chat will be made available beginning Monday, September 12, 2022 at 7:00 a.m. E

  • GlobeNewswire

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 35,000 shares of Kala Pharmaceuticals common stock to two new employees. The stock options were granted on August 15, 2022. The g

  • GlobeNewswire

    Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

    ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common

Advertisement
Advertisement